Lyell Immunopharma (NASDAQ:LYEL - Free Report) had its price objective hoisted by HC Wainwright to $10.00 in a research report report published on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.
Separately, Wall Street Zen raised shares of Lyell Immunopharma to a "hold" rating in a research report on Friday, June 6th.
Check Out Our Latest Report on LYEL
Lyell Immunopharma Stock Up 6.7%
Lyell Immunopharma stock traded up $0.60 during trading hours on Tuesday, reaching $9.59. 91,111 shares of the company's stock were exchanged, compared to its average volume of 69,572. The firm's 50 day simple moving average is $9.10 and its 200 day simple moving average is $11.15. Lyell Immunopharma has a twelve month low of $7.65 and a twelve month high of $45.42. The firm has a market capitalization of $142.03 million, a PE ratio of -0.38 and a beta of -0.26.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($3.60) EPS for the quarter, beating the consensus estimate of ($3.80) by $0.20. The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 73.66% and a negative net margin of 514,649.22%. Analysts anticipate that Lyell Immunopharma will post -0.78 EPS for the current year.
Institutional Trading of Lyell Immunopharma
Several large investors have recently made changes to their positions in the company. Barclays PLC boosted its holdings in Lyell Immunopharma by 7.4% in the fourth quarter. Barclays PLC now owns 258,380 shares of the company's stock worth $165,000 after acquiring an additional 17,765 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Lyell Immunopharma by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 94,320 shares of the company's stock worth $60,000 after purchasing an additional 20,542 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Lyell Immunopharma by 13.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company's stock worth $197,000 after purchasing an additional 36,555 shares in the last quarter. Graham Capital Management L.P. bought a new position in shares of Lyell Immunopharma in the 4th quarter worth $33,000. Finally, RPO LLC acquired a new stake in Lyell Immunopharma in the 4th quarter valued at $42,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.
About Lyell Immunopharma
(
Get Free Report)
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Featured Stories
Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
